CHD

Featured Article

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.

Latest Features

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Researchers argue that elevated coronary artery calcium scores increase the risk of adverse cardiovascular events even in young patients.

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Evidence is lacking to support oxygen therapy for acute myocardial infarction.

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

A review of cardiovascular disease burden, particularly coronary heart disease, in HIV/AIDS.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

Latest News

Measuring Visceral Adipose Tissue With DXA to Predict Atherosclerotic CVD

Measuring Visceral Adipose Tissue With DXA to Predict Atherosclerotic CVD

Fourteen percent of study participants experienced incident athersclerotic cardiovascular disease events.

Gray Hair Predictive of Coronary Artery Disease in Men

Gray Hair Predictive of Coronary Artery Disease in Men

Hair whitening score, hypertension, and dyslipidemia were all independent predictors of atherosclerotic coronary artery disease.

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

Fasting pancreatic polypeptide may be a marker for macrovascular disease.

Recurrent MI Risk, CHD Events Increased with Statin Intolerance

Recurrent MI Risk, CHD Events Increased with Statin Intolerance

Patients with statin intolerance had a 36% higher rate of recurrent myocardial infarction compared with patients with high statin adherence.

ACC Updated Criteria: Coronary Revascularization in Stable Ischemic Heart Disease

ACC Updated Criteria: Coronary Revascularization in Stable Ischemic Heart Disease

Revised coronary revascularization criteria rated whether coronary interventions are appropriate in tables organized according to practice patterns.

Increased Cardiovascular Disease Risk With Darunavir Therapy

Increased Cardiovascular Disease Risk With Darunavir Therapy

Risk of cardiovascular disease gradually increased in patients undergoing darunavir therapy.

Multi-Protein Blood Test Sensitive, Effective in Coronary Artery Disease Screening

Multi-Protein Blood Test Sensitive, Effective in Coronary Artery Disease Screening

The HART test has been found to be more accurate than standard diagnostic methods in identifying coronary artery disease.

Rivaroxaban Trial Meets End Point Ahead of Schedule

Rivaroxaban Trial Meets End Point Ahead of Schedule

Rivaroxaban met its primary end point well ahead of the scheduled March 2018 trial conclusion.

Coronary Artery Disease Mortality Predicted by Anemia

Coronary Artery Disease Mortality Predicted by Anemia

Low hemoglobin levels independently predicted all-cause, cardiovascular, and noncardiovascular mortality in patients with coronary artery disease.

Renin-Angiotensin System Inhibitors in Coronary Artery Disease Without Heart Failure

Renin-Angiotensin System Inhibitors in Coronary Artery Disease Without Heart Failure

Renin-angiotensin system inhibitors reduced cardiovascular events in patients with coronary artery disease when compared with placebo but not active controls.

Sign Up for Free e-Newsletters